Pharmaceutical composition

Abstract

A pharmaceutical composition which comprises an insulin sensitizer in combination with an anorectic, which is useful as an agent for preventing or treating diabetes.

1 . A pharmaceutical composition which comprises an insulin sensitizer in combination with an anorectic.  
     
     
         2 . A pharmaceutical composition according to  claim 1 , wherein the insulin sensitizer is a compound of the formula:  
       
         
           
           
               
               
           
         
       
       wherein R represents a hydrocarbon group or a heterocyclic group, each of which may be substituted; Y represents a group of the formula: —CO—, —CH(OH)— or —NR 3 — where R 3  represents an alkyl group that may be substituted; m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a chemical bond or a bivalent aliphatic hydrocarbon group having 1 to 7 carbon atoms; Q represents oxygen or sulfur; R 1  represents hydrogen or an alkyl group; ring E may have further 1 to 4 substituents, which may form a ring in combination with R 1 ; L and M respectively represent hydrogen or may be combined with each other to form a chemical bond; or a salt thereof.  
     
     
         3 . A pharmaceutical composition according to  claim 1 , wherein the insulin sensitizer is pioglitazone hydrochloride, troglitazone, rosiglitazone or 4-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzyl]isoxazolidin-3,5-dione.  
     
     
         4 . A pharmaceutical composition according to  claim 2 , wherein the compound of the formula (I) or salt thereof is pioglitazone hydrochloride.  
     
     
         5 . A pharmaceutical composition according to  claim 1 , wherein the anorectic is a central anorectic.  
     
     
         6 . A pharmaceutical composition according to  claim 5 , wherein the central anorectic is mazindol.  
     
     
         7 . A pharmaceutical composition according to  claim 1 , wherein the insulin sensitizer is pioglitazone hydrochloride and the anorectic is mazindol.  
     
     
         8 . A pharmaceutical composition according to  claim 1 , which is for preventing or treating diabetes.  
     
     
         9 . A pharmaceutical composition according to  claim 8 , wherein the diabetes is noninsulin-dependent diabetes mellitus.  
     
     
         10  A pharmaceutical composition according to  claim 2 , wherein the compound of the formula (I) or salt thereof is troglitazone.  
     
     
         11 . A pharmaceutical composition according to  claim 2 , wherein the compound of the formula (I) or salt thereof is rosiglitazone or its maleate.  
     
     
         12 . A pharmaceutical composition according to  claim 1 , which is for preventing or treating diabetic complications.  
     
     
         13 . A pharmaceutical composition according to  claim 1 , which is for preventing or treating impaired glucose tolerance.  
     
     
         14 . A pharmaceutical composition which comprises an insulin sensitizer and is used in combination with an anorectic.  
     
     
         15 . A method for preventing or treating diabetes in a mammal in need thereof, which comprises administering to said mammal an effective amount of an insulin sensitizer in combination with an anorectic.  
     
     
         16 . A method for preventing or treating diabetic complications in a mammal in need thereof, which comprises administering to said mammal an effective amount of an insulin sensitizer in combination with an anorectic.  
     
     
         17 . A method for preventing or treating impaired glucose tolerance in a mammal in need thereof, which comprises administering to said mammal an effective amount of an insulin sensitizer in combination with an anorectic.  
     
     
         18 . Use of an insulin sensitizer for the manufacture of a pharmaceutical preparation for treating diabetes which is used in combination with an anorectic.  
     
     
         19 . Use of an insulin sensitizer for the manufacture of a pharmaceutical preparation for treating diabetic complications which is used in combination with an anorectic.  
     
     
         20 . Use of an insulin sensitizer for the manufacture of a pharmaceutical preparation for treating impaired glucose tolerance which is used in combination with an anorectic.  
     
     
         21 . A method for reducing the side effects of an insulin sensitizer or/and an anorectic administered to a diabetic mammal, which comprises administering to said mammal an effective amount of them.